Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, comparing standard care in the control group, with standard care plus the addition of injection of liposomal bupivacaine in the experimental group.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Steven Orebaugh; University of Pittsburgh
• Collaborator: Pacira Pharmaceuticals, Inc
• Treatments: Bupivacaine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Adult patients up to age 65 years, undergoing elective, ambulatory, arthroscopic rotator cuff repair.

Exclusion Criteria:

• Pregnancy, coagulopathy, allergy to bupivacaine, renal failure, hepatic insufficiency, and/or inappropriate candidate for usual therapy (specifically, if unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block).